Pulmonary Infections and Community Associated Methicillin Resistant Staphylococcus Aureus: A Dangerous Mix?

Paediatric Respiratory Reviews

Volumn 12, Issue 3, 2011, Pages 182-189

  Shilo, Natalie ^a   Quach, Caroline ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Community Associated Methicillin Resistant Staphylococcus aureus CA MRSA ; Community associated pneumonia; Complicated pneumonia; Cystic fibrosis; Empyaema

Indexed keywords

CHLORHEXIDINE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; LEVOFLOXACIN; LINEZOLID; PANTON VALENTINE LEUKOCIDIN; PSEUDOMONIC ACID; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BACTERIUM DETECTION; BONE MARROW SUPPRESSION; CLINICAL FEATURE; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; THORAX RADIOGRAPHY;

ANTI-BACTERIAL AGENTS; CHILD; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; CYSTIC FIBROSIS; DISEASE PROGRESSION; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS;

EID: 79959722064     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2010.10.007     Document Type: Review

References (59)

1. Sawicki G.S., Lu F.L., Valim C., Cleveland R.H., Colin A.A. Necrotising Pneumonia is an Increasingly Detected Complication of Pneumonia in Children. Eur Respir J. 2008, 31:1285-1291.
2. Schultz K.D., Fan L.L., Pinsky J., Ochoa L., Smith E.O., Kaplan S.L., et al. The Changing Face of Pleural Empyemas in Children: Epidemiology and Management. Pediatrics 2004, 113:1735-1740.
3. Wallin T.R., Hern G., Frazee B.W. Community-Associated Methicillin-Resistant Staphylococcus aureus. Emerg Med Clin North Am 2008, 26:431-455.
4. Carcillo J.A., Castillo L., Thomas J., Kissoon N. Recognizing, Understanding, and Treating Critical Community acquired methicillin-resistant Staphyloccus aureus Infection in Children. Pediatr Crit Care Med 2009, 10:405-407.
5. Gillet Y., Vanhem S., Lina G., Bes M., Vandenesch F., Floret D., Etienne J. Factors Predicting Mortality in Necrotizing Community-Acquired Pneumonia Caused by Staphyloccus aureus Containing Panton-Valentine Leukocidin. Clin Infect Dis. 2007, 45:315-321.
6. CDC. Severe Methicillin-Resistant Staphylococcus aureus Community-Acquired Pneumonia Associated with Influenza - Louisiana and Georgia, December 2006 - January 2007. MMWR. 2007; 56: 325-9.
7. Hidron A.I., Low C.E., Honig E.G., Blumberg H.M. Emergence of Community-Acquired Methicillin-Resistant Staphylococcus aureus Strain USA300 as a Cause of Necrotizing Community-Onset Pneumonia. Lancet. 2009, 9:384-392.
8. Tietz A., Frei R., Widmer A.F. Transatlantic Spread of the USA300 Clone of MRSA. N Engl J Med. 2005, 353:532-533.
9. Pantosti A., Venditti M. What is MRSA?. Eur Respirir J. 2009, 34:1190-1196.
10. Bartels M.D., Boye K., Rhod Larsen A., Skov R., Westh H. Rapid Increase of Genetically Diverse Methicillin-Resistant Staphylococcus aureus, Copenhagen, Denmark. Emerg Infect Dis. 2007, 13:1533-1540.
11. Del Giudice P., Blanc V., Durupt F., Bes M., Martinez J.P., Coumillon E., et al. Emergence of Two Populations of Methicillin-Resistant Staphylococcus aureus with Distinct Epidemiological, Clinical and Biological Features, Isolated from Patients with Community-Acquired Skin Infections. Br J Dermatol 2006, 154:118-124.
12. DeLeo F.R., Otto M., Kreiswirth B.N., Chambers H.F. Community-Associated Methicillin-resistant Staphylococcus aureus. Lancet 2010, 375:1557-1568.
13. Boyle-Vavra S., Daum R.S. Community-Acquired Methicillin-Resistant Staphyloccus aureus: The Role of Panton-Valentine leukocidin. Lab Invest 2007, 87:3-9.
14. Ebert M.D., Sheth S., Fishman E.K. Necrotizing Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: An Increasing Cause of " Mayhem in the Lung" Emerg Radiol 2009, 16:159-162.
15. CDC. Four Pediatric Deaths from Community-Acquired Methicillin-Resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. MMWR 1999; 48: 707-10.
16. Miller L.G., Kaplan S.L. Staphylococcus aureus: A Community Pathogen. Infect Dis Clin North Am 2009, 23:35-42.
17. Gonzalez B., Rueda A.M., Shelbourne S.A., Musher D.M., Hamill R.J., Hulten K.G. Community-Associated Strains of Methicillin-Resistant Staphylococcus aureus as the Cause of Healthcare-Associated Infection. Infect Control Hosp Epidemiol 2006, 27:1051-1056.
18. Bradley S.F. Staphylococcus aureus Pneumonia: Emergence of MRSA in the Community. Semin Respir Crit Care Med 2005, 26:643-649.
19. Johnston B.L., Conly J.M. Community - Associated Methicillin-Resistant Staphylococcus aureus: Continuing to Evolve. Can J Infect Dis Med Microbiol. 2008, 19:161-163.
20. Barton M., Hawkes M., Moore D., Conly J., Nicolle L., Allen U., et al. Guidelines for the Prevention and Management of Community-Associated Methicillin-Resistant Staphylococcus aureus: A Perspective for Canadian Health Care Practitioners. Can J Infect Dis Med Microbiol 2006, 17(Suppl C):4C-24C.
21. Tacconelli E., De Angelis G. Pneumonia due to Methicillin-Resistant Staphylococcus aureus: Clinical Features, Diagnosis and Management. Curr Opin Pulm Med 2009, 15:218-222.
22. Defres S., Marwick C., Nathwani D. MRSA as a Cause of Lung Infection Including Airway Infection, Community-Acquired Pneumonia and Hospital-Acquired Pneumonia. Eur Respir J 2009, 34:1470-1476.
23. Moran G.J., Krishnadasan A., Gorwitz R.J., Fosheim G.E., McDougal L.K., Carey R.B., et al. Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department. N Engl J Med 2006, 355:666-674.
24. Ren C.L., Morgan W.J., Konstan M.W., Schechter M.S., Wagener J.S., Fisher K.A., et al. Presence of Methicillin Resistant Staphylococcus aureus in Respiratory Cultures from Cystic Fibrosis Patients Is Associated with Lower Lung Function. Pediatr Pulmonol 2007, 42:513-518.
25. Kaplan S.L., Hulten K.G., Gonzalez B.E., Hammerman W.A., Lamberth L., Versalovic J., et al. Three-Year Surveillance of Community-Acquired Staphylococcus aureus Infections in Children. Clin Infect Dis 2005, 40:1785-1791.
26. Gonzalez B.E., Hulten K.G., Dishop M.K., Lamberth L.B., Hammerman W.A., Mason E.O., et al. Pulmonary Manifestations in Children with Invasive Community-Acquired Staphylococcus aureus Infection. Clin Infect Dis 2005, 41:583-590.
27. Zetola N., Francis J.S., Nuremberger E.L., Bishai W.R. Community-Acquired Methicillin-Resistant Staphylococcus aureus: An Emerging Threat. Lancet 2005, 5:275-285.
28. Labandeira-Rey M., Couzon F., Boisset S., Brown E.L., Bes M., Benito Y., et al. Staphylococcus aureus Panton-Valentine Leukocidin Causes Necrotizing Pneumonia. Science 2007, 315:1130-1133.
29. Gillet Y., Issartel B., Vanhem S., Fournet J.C., Lina G., Bes M., Vandenesch F., Piemont Y., Brousse N., Floret D., Etienne J. Association between Staphyloccus aureus Strains Carrying Gene for Panton-Valentine Leukocidin and Highly Lethal Necrotizing Pneumonia in Young Immunocompetent Patients. Lancet 2002, 359:753-759.
30. Odetola F.O., Gebremariam A., Freed G.L. Patient and Hospital Correlates of Clinical Outcomes and Resource Utilization in Severe Pediatric Sepsis. Pediatrics 2007, 119:487-494.
31. Kallen A.J., Brunkard J., Moore Z., Budge P., Arnold K.E., Fosheim K., et al. Staphylococcus aureus Community-Acquired Pneumonia During the 2006 to 2007 Influenza Season. Ann Emerg Med. 2009, 53:358-365.
32. Finelli L., Fiore A., Dhara R., Brammer L., Shay D.K., Kamimoto L., et al. Influenza-Associated Pediatric Mortality in the United States: Increase of Staphylococcus aureus Coinfection. Pediatrics. 2008, 122:805-811.
33. CDC. Surveillance for Pediatric Deaths Associated with 2009 Pandemic Influenza A (H1N1) Virus Infection - United States, April-August 2009. MMWR. 2009; 58:941-7.
34. Napoliano L.M., Brunsvold M.E., Reddy R.C., Hyzy R.C. Community-Acquired Methicillin-Resistant Staphylococcus aureus Pneumonia and ARDS. Chest 2009, 136:1407-1412.
35. Creel A.M., Durham S.H., Benner K.W., Alten J.A., Winkler M.K. Severe Invasive Community-Associated Methicillin-Resistant Staphylococcus aureus Infections in Previously Healthy Children. Pediatr Crit Care Med 2009, 10:323-327.
36. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007, 44(Suppl 2):S27-72.
37. Fergie J., Purcell K. The Treatment of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections. Pediatr Infect Dis J 2008, 27:67-68.
38. Le J., Lieberman J.M. Management of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections in Children. Pharmacother 2006, 26:1758-1770.
39. Dartois N., Castaing N., Gandjini H., Cooper A. Tigecycline versus Levofloxacin for the Treatment of Community-Acquired Pneumonia: European Experience. J Chemother 2008, 20(Suppl 1):28-35. Tigecycline 313 Study Group.
40. Koomanachai P., Crandon J.L., Banevicius M.A., Peng L., Nicolau D.P. Pharmacodynamic Profile of Tigecycline against Methicillin-Resistant Staphylococcus aureus in an Experimental Pneumonia Model. Antimicrob Agents Chemother 2009, 53:5060-5063.
41. Laohavaleeson S., Tessier P.R., Nicolau D.P. Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus. Strains Antimicrob Agents Chemother 2008, 52:2389-2394.
42. Chen A.E., Cantey J.B., Carroll K.C., Ross T., Speser S., Siberry G.K. Importance of colonization site in the current epidemic of staphylococcal skin abscesses. Pediatrics 2010, 125:618-624.
43. Faden H., Lesse A.J., Trask J., Hill J.A., Hess D.J., Dryja D., et al. Discordance between Staphylococcus aureus Nasal Colonization and Skin Infections in Children. Pediatr Infect Dis J 2009, 28:244-246.
44. Lee G.M., Huang S.S., Rifas-Shiman S.L., Hinrichsen V.L., Pelton S.I., Kleinman K., et al. Epidemiology and Risk Factors for Staphylococcus aureus Colonization in Children in the post-PCV7 Era. BMC Infect Dis 2009, 9:110.
45. Loeb M., Main C., Walker-Dilks C., Eady A. Antimicrobial Drugs for Treating Methicillin-Resistant Staphylococcus aureus Colonization. Cochrane Database Syst Rev 2008, 4. CD003340.
46. Simor A.E., Phillips E., McGeer A., Konvalinka A., Loeb M., Devlin H.R., et al. Randomized Controlled Trial of Chlorhexidine Gluconate for Washing, Intranasal Mupirocin, and Rifampin and Doxycycline Versus No Treatment for the Eradication of Methicillin-Resistant Staphylococcus aureus Colonization. Clin Infect Dis. 2007, 44:178-185.
47. Grundmann H., Aires-de-Sousa M., Boyce J., Tiemersma E. Emergence and Resurgence of Methicillin-Resistant Staphylococcus aureus as a public-health threat. Lancet 2006, 368:874-875.
48. Miall L.S., McGinley N.T., Brownlee K.G., Conway S.P. Methicillin-Resistant Staphylococcus aureus (MRSA) Infection in Cystic Fibrosis. Arch Dis Child. 2001, 84:160-162.
49. Branger C., Fournier J.M., Loulergue J., Bouvet A., Goullet P., Boutonnier A., et al. Epidemiology of Staphylococcus aureus in Patients with Cystic Fibrosis. Epidemiol Infect. 1994, 112:489-500.
50. Emerson J., McNamara S., Buccat A.M., Worrell K., Burns J.L. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol. 2010, 45:363-370.
51. Solis A., Brown D., Hughes J., van saene H.K.F., Heaf D.P. Methicillin-Resistant Staphylococcus aureus in Children With Cystic Fibrosis: An Eradication Protocol. Pediatr Pulmonol 2003, 36:189-195.
52. Dasenbrook E.C., Merlo C.A., Diener-West M., Lechtzin N., Boyle M.P. Persistent Methicillin-Resistant Staphylococcus aureus and Rate of FEV1 Decline in Cystic Fibrosis. Am J Respir Crit Care Med 2008, 178:814-821.
53. Sawicki G.S., Rasouliyan L., Pasta D.J., Regelmann W.E., Wagener J.S., Waltz D.A., et al. The Impact of Incident Methicillin-Resistant Staphylococcus aureus Detection on Pulmonary Function in Cystic Fibrosis. Pediatr Pulmonol 2008, 43:1117-1123.
54. Campana S., Cocchi P., Doring G., Taccetti G. Complex Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Isolates from Children with Cystic Fibrosis in the Era of Epidemic Community - Associated Methicillin-Resistant S. aureus. J Clin Microbiol. 2007, 45. 3146-7-7.
55. Stone A., Quittell L., Zhou J., Alba L., Bhat M., DeCelie-Germana J., et al. Staphylococcus aureus Nasal Colonization Among Pediatric Cystic Fibrosis Patients and their Household Contacts. Pediatr Infect Dis J 2009, 28:895-899.
56. Doe S.J., McSorley A., Isalska B., Kearns A.M., Bright-Thomas R., Brennan A.L., et al. Patient Segregation and Aggressive Antibiotic Eradication Therapy can Control Methicillin-Resistant Staphylococcus aureus at Large Cystic Fibrosis Centres. J Cyst Fibros. 2010, 9:104-109.
57. Hill R.L.R., Kearns A.M., Nash J., North S.E., Pike R., Newson T., et al. Linezolid-Resistant ST36 Methicillin-Resistant Staphylococcus aureus Associated with Prolonged Linezolid Treatment in two Pediatric Cystic Fibrosis Patients. J Antimicrob Chemother. 2010, 65. 442-5 2010.
58. Elizur A., Orschein R.C., Ferkol T.W., Dunne W.M., Storch G.A., Cannon C.L. Transmission of Panton- Valentine Leukocidin-Positive Staphylococcus aureus between Patients with Cystic Fibrosis. J Pediatr 2007, 4:90-92.
59. Elizur A., Orschein R.C., Ferkol T.W., Atkinson J.J., Dunne W.M.J.R., Buller R.S., et al. Panton-Valentine Leukocidin-Positive Methicillin-Resistant Staphylococcus aureus Lung Infection in Patients With Cystic Fibrosis. Chest 2007, 131:1718-1725.